The 6 analysts offering 12-month price forecasts for Crinetics Pharmaceuticals Inc have a median target of 36.00, with a high estimate of 43.00 and a low estimate of 23.00. The median estimate represents a +155.41% increase from the last price of 14.10.
The current consensus among 6 polled investment analysts is to Buy stock in Crinetics Pharmaceuticals Inc. This rating has held steady since December, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.63
Reporting Date May 18
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.